File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence

TitleNeurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence
Authors
KeywordsLong-term methylphenidate treatment
ADHD
Adverse neuropsychiatric events
Mood
Anxiety
Issue Date2019
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/neubiorev
Citation
Neuroscience & Biobehavioral Reviews, 2019, v. 107, p. 945-968 How to Cite?
AbstractMethylphenidate (MPH), the most common medication for children with Attention Deficit/Hyperactivity Disorder (ADHD) in many countries, is often prescribed for long periods of time. Any long-term psychotropic treatment in childhood raises concerns about possible adverse neurological and psychiatric outcomes. We aimed to map current evidence regarding neurological and psychiatric outcomes, adverse or beneficial, of long-term MPH (> 1 year) treatment in ADHD. We coded studies using a “traffic light” system: Green: safe/favours MPH; Amber: warrants caution; Red: not safe/not well-tolerated. Un-categorisable study findings were coded as “Unclear”. Although some evidence suggests an elevated risk of psychosis and tics, case reports describe remission on discontinuation. Several studies suggest that long-term MPH may reduce depression and suicide in ADHD. Evidence suggests caution in specific groups including pre-school children, those with tics, and adolescents at risk for substance misuse. We identified a need for more studies that make use of large longitudinal databases, focus on specific neuropsychiatric outcomes, and compare outcomes from long-term MPH treatment with outcomes following shorter or no pharmacological intervention.
Persistent Identifierhttp://hdl.handle.net/10722/278591
ISSN
2017 Impact Factor: 8.037
2015 SCImago Journal Rankings: 5.290

 

DC FieldValueLanguage
dc.contributor.authorKrinzinge, H-
dc.contributor.authorHall, CL-
dc.contributor.authorGroom, MJ-
dc.contributor.authorAnsari, MT-
dc.contributor.authorBanaschewsk, T-
dc.contributor.authorBuitelaar, JK-
dc.contributor.authorCarucc, S-
dc.contributor.authorCoghill, D-
dc.contributor.authorDanckaerts, M-
dc.contributor.authorDittmann, RW-
dc.contributor.authorFalissard, B-
dc.contributor.authorGaras, P-
dc.contributor.authorInglis, SK-
dc.contributor.authorKovshoff, H-
dc.contributor.authorKochhar, P-
dc.contributor.authorMcCarthy, S-
dc.contributor.authorNagy, P-
dc.contributor.authorNeubert, A-
dc.contributor.authorRoberts, S-
dc.contributor.authorSayal, K-
dc.contributor.authorSonuga-Barke, E-
dc.contributor.authorWong, ICK-
dc.contributor.authorXia, J-
dc.contributor.authorZuddas, A-
dc.contributor.authorHollis, C-
dc.contributor.authorKonrad, K-
dc.contributor.authorLiddle, EB-
dc.contributor.authorThe ADDUCE Consortium,-
dc.date.accessioned2019-10-21T02:10:23Z-
dc.date.available2019-10-21T02:10:23Z-
dc.date.issued2019-
dc.identifier.citationNeuroscience & Biobehavioral Reviews, 2019, v. 107, p. 945-968-
dc.identifier.issn0149-7634-
dc.identifier.urihttp://hdl.handle.net/10722/278591-
dc.description.abstractMethylphenidate (MPH), the most common medication for children with Attention Deficit/Hyperactivity Disorder (ADHD) in many countries, is often prescribed for long periods of time. Any long-term psychotropic treatment in childhood raises concerns about possible adverse neurological and psychiatric outcomes. We aimed to map current evidence regarding neurological and psychiatric outcomes, adverse or beneficial, of long-term MPH (> 1 year) treatment in ADHD. We coded studies using a “traffic light” system: Green: safe/favours MPH; Amber: warrants caution; Red: not safe/not well-tolerated. Un-categorisable study findings were coded as “Unclear”. Although some evidence suggests an elevated risk of psychosis and tics, case reports describe remission on discontinuation. Several studies suggest that long-term MPH may reduce depression and suicide in ADHD. Evidence suggests caution in specific groups including pre-school children, those with tics, and adolescents at risk for substance misuse. We identified a need for more studies that make use of large longitudinal databases, focus on specific neuropsychiatric outcomes, and compare outcomes from long-term MPH treatment with outcomes following shorter or no pharmacological intervention.-
dc.languageeng-
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/neubiorev-
dc.relation.ispartofNeuroscience & Biobehavioral Reviews-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectLong-term methylphenidate treatment-
dc.subjectADHD-
dc.subjectAdverse neuropsychiatric events-
dc.subjectMood-
dc.subjectAnxiety-
dc.titleNeurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence-
dc.typeArticle-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.neubiorev.2019.09.023-
dc.identifier.pmid31545988-
dc.identifier.scopuseid_2-s2.0-85074755405-
dc.identifier.hkuros308226-
dc.identifier.volume107-
dc.identifier.spage945-
dc.identifier.epage968-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats